Table 2: Allele frequencies of MICA in patients with GD with and without TAO.

MICA alleleControls ( )Non-TAO ( )TAO ( )GD ( )

MICA*00217 (12.3%)2 (4.2%)6 (14.3%)8 (9.8%)
MICA*00410 (7.1%)1 (2.1%)0 (0%)1 (1.2%)
MICA*0060 (0%)1 (2.1%)0 (0%)1 (1.2%)
MICA*0075 (3.6%)0 (0%)1 (2.4%)1 (1.2%)
MICA*00829 (20.7%)1 (2.1%)a7 (16.7%)8 (8.9%)
MICA*0097 (5.0%)3 (6.3%)1 (2.4%)4 (4.4%)
MICA*01027 (19.3%)20 (41.7%)b13 (31.0%)33 (36.7%)
MICA*0114 (2.9%)0 (0%)0 (0%)0 (0%)
MICA*01214 (10.0%)8 (16.7%)3 (7.1%)11 (12.2%)
MICA*0171 (0.7%)0 (0%)0 (0%)0 (0%)
MICA*0191 (0.7%)2 (4.2%)1 (2.4%)3 (3.3%)
MICA*02714 (10.0%)6 (12.5%)7 (16.7%)13 (14.4%)
MICA*0451 (0.7%)0 (0%)0 (0%)0 (0%)
MICA*04910 (7.1%)4 (8.3%)3 (7.1%)7 (7.8%)

MICA: major histocompatibility complex (MHC) class I chain-related gene A; TAO: with thyroid associated ophthalmopathy; non-TAO: without thyroid associated ophthalmopathy; GD: Graves’ disease; C: healthy control subjects; allele frequencies of MICA were in the Hardy-Weinberg equilibrium (P < 0.349); aP < 0.001 ( < 0.014), OR = 0.08 (95% CI, 0.01–0.62) versus C; bP < 0.003 ( < 0.042), OR = 2.99 (95% CI, 1.47–6.09) versus C.